Concentration on the innovative pharmaceuticals business through the transfer of the generic pharmaceuticals business and plants

A business portfolio restructuring involving the transfer of the generic pharmaceuticals business, excluding authorized generics, and the Takaoka and Inami plants to external organizations, in order to concentrate management resources on the prescription innovative pharmaceuticals business.